Sinopharm’s efficacy rate puts the company’s vaccine behind Moderna’s 94.5 percent and Pfizer-BioNTech’s 95 percent, but ahead of AstraZeneca’s 70 percent. But data from the Phase 3 trial has not yet been released, with UAE officials only giving a few headline numbers. Sinopharm did not immediately respond to requests for comment Wednesday.

Phase 3 trial data has been released about the vaccine candidates from U.S.-based biotech company Moderna, which is partnering with the National Institutes of Health; U.S. pharmaceutical giant Pfizer and its German partner, biotech firm BioNTech; and British-Swedish pharmaceutical company AstraZeneca and its partner, the University of Oxford.

The vaccine is one of two developed by Sinopharm that have been granted emergency-use status within China for preventing infection with covid-19, the disease caused by the novel coronavirus.

Already, Sinopharm’s coronavirus vaccines are probably the most widely used around the world. The company’s chairman told Chinese media last month that nearly 1 million people had received doses, including Chinese nationals working abroad. China has come …continued .
[Source: Washington Post]